- ALK Canada announced that neffy, the first needle-free epinephrine nasal spray, is now available across Canada following Health Canada approval in April 2026. It is indicated for the emergency treatment of anaphylaxis in adults and children weighing 30 kg or more.
- neffy is approved to treat severe allergic reactions triggered by foods, insect stings or bites, medicines, other allergens, exercise, or unknown causes, providing an alternative to traditional epinephrine auto-injectors.
- Healthcare experts and patient advocates say the needle-free nasal spray could reduce hesitation and improve confidence in administering epinephrine during emergencies, when rapid treatment is critical.
- A OnePoll survey commissioned by ALK Canada found that 49% of Canadians would not feel confident using an epinephrine auto-injector in an emergency, highlighting the need for more accessible treatment options for people at risk of anaphylaxis.
Takeaways:
The availability of a nasal spray should broaden the addressable market for emergency epinephrine by reducing needle anxiety and administration hesitation, potentially increasing carriage and use among people who previously avoided or delayed treatment. Because neffy is positioned as an alternative to auto-injectors rather than a replacement, it can expand the overall category and create new brand share opportunities for ALK, especially if schools, workplaces, and families adopt it alongside or instead of traditional devices.
Source: ALK
